Oncology · Clinical trials
Cutaneous Squamous Cell Carcinoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About cutaneous squamous cell carcinoma — and why its trials are hard
Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer, arising from keratinocytes and driven largely by cumulative ultraviolet exposure and immunosuppression. Most cases are cured by surgery or radiotherapy, but a minority become locally advanced or metastatic, historically carrying a poor prognosis with limited systemic options such as platinum chemotherapy or EGFR inhibitors that lacked durable benefit. CSCC has one of the highest tumor mutational burdens of any malignancy, making it highly responsive to immune checkpoint blockade. The 2018 approval of cemiplimab, the first agent specifically approved for advanced CSCC, transformed the treatment landscape, followed by pembrolizumab. PD-1 inhibition now yields durable responses in roughly a third to nearly half of advanced patients. Ongoing research addresses neoadjuvant immunotherapy, organ-transplant recipients (in whom checkpoint inhibitors risk graft rejection), and patients ineligible for immunotherapy, who remain an area of substantial unmet need.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| cemiplimab (Libtayo) | 2018 | Metastatic or locally advanced CSCC not curable by surgery or radiation | EMPOWER-CSCC-1 (Study 1540) and Study 1423 | Objective response rate (ORR) | ORR approximately 47%, with a majority of responses durable beyond 6 months; first agent approved specifically for advanced CSCC |
| pembrolizumab (Keytruda) | 2020 | Recurrent or metastatic, and locally advanced CSCC not curable by surgery/radiation | KEYNOTE-629 | Objective response rate (ORR) | ORR approximately 35% in recurrent/metastatic disease; durable responses supporting a second checkpoint option |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in cutaneous squamous cell carcinoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| cetuximab (EGFR inhibitor) — Small phase II studies (e.g., French GORTEC-derived cohorts); never FDA-approved for CSCC | Modest, non-durable responses; disease control often short-lived | EGFR pathway not the dominant driver; superseded by highly effective PD-1 blockade in a high-mutational-burden tumor |
Choosing the right endpoint
Primary endpoints that matter in cutaneous squamous cell carcinoma trials
- Objective response rate (ORR) — Primary endpoint in the registrational single-arm CSCC checkpoint trials; assessed by independent review
- Duration of response (DoR) — Critical in CSCC given emphasis on durability of immunotherapy benefit; many responses exceed 12 months
- Progression-free survival (PFS) — Secondary endpoint reflecting disease control over time
- Overall survival (OS) — Difficult to interpret in single-arm designs but tracked in long-term follow-up
- Pathologic complete response (pCR) — Emerging endpoint in neoadjuvant CSCC trials of PD-1 inhibitors prior to surgery
How iNGENū runs cutaneous squamous cell carcinoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Cutaneous Squamous Cell Carcinoma clinical trials — FAQs
Why is CSCC so responsive to immunotherapy?
Can organ transplant recipients receive checkpoint inhibitors for CSCC?
What is standard treatment for early CSCC?
Ready to discuss your cutaneous squamous cell carcinoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal